

Dealdoc**Collaborative R&D agreement for innovative drugs**

ChemRar High-Tech Center
Abbott Laboratories

Jul 09 2012

Collaborative R&D agreement for innovative drugs

Companies:	ChemRar High-Tech Center Abbott Laboratories
Announcement date:	Jul 09 2012
Deal value, US\$m:	n/d

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Jul 09 2012
Industry sectors:	Bigpharma Pharmaceutical
Therapy areas:	Infectives » Viral
Technology types:	Biological compounds Small molecules
Deal components:	Collaborative R&D Development
Geographic focus:	Europe » Russia

Financials

Deal value, US\$m:	n/d
---------------------------	-----

Termsheet

ChemDiv Research Institute and Abbott they have signed an agreement to launch several R&D projects in Russia.

This initiative is aimed to broaden therapeutic opportunities for the patients in Russia and to contribute to building an innovative pharmaceutical industry in Russia.

This collaboration is aligned with the Russian Government initiative to modernize the Russian pharmaceutical industry as envisioned in the Development Strategy for the Pharmaceutical Industry through 2020.

It was also announced that ChemRar's R&D company, Intellectual Dialog, launched a research project with Abbott aimed at prevention and treatment of selected viral diseases impacting children and the elderly.

Press Release

ChemDiv Research Institute Announces R&D Collaborations With Abbott in Russia

MOSCOW, Jul 09, 2012 (MARKETWIRE via COMTEX) -- ChemDiv Research Institute (CDRI) at the ChemRar Hi-Tech Centre and Abbott, a global healthcare company, announced at the St. Petersburg International Economic Forum that they have signed an agreement to launch several R&D projects in Russia. This initiative is aimed to broaden therapeutic opportunities for the patients in Russia and to contribute to building an innovative pharmaceutical industry in Russia.

The first collaboration between CDRI, the research entity of ChemRar Hi-Tech Centre, and Abbott will focus on creating an advanced new forms of the existing Abbott's pharmaceutical products to increase patient's compliance and decrease medicine intake. These goals will be accomplished by developing new technologies and by introducing new medicine formulations. In addition to the abovementioned, there are

some other ongoing discussions between CDRI and Abbott regarding several programs for joint small molecule medicine's development and enhancement.

It was also announced that ChemRar's R&D company, Intellectual Dialog, launched a research project with Abbott aimed at prevention and treatment of selected viral diseases impacting children and the elderly. Intellectual Dialog will conduct discovery research in collaboration with Abbott.

"CDRI is actively involved in both developing new molecules and improving existing drugs, covering the full cycle from pre-clinical development through manufacturing. Our collaboration with global healthcare leader Abbott will draw on the company's expertise and technologies and Russia's significant scientific potential to effectively develop new products of the highest quality based on existing drugs," said Nikolay Savchuk, Chairman at CDRI.

This collaboration is aligned with the Russian Government initiative to modernize the Russian pharmaceutical industry as envisioned in the Development Strategy for the Pharmaceutical Industry through 2020.

About ChemDiv Research Institute: ChemDiv Research Institute (CDRI) is a fully integrated discovery and development Contract Research Organization (CRO), subsidiary of ChemDiv, Inc of San Diego CA, established at ChemRar High Tech Center in Khimki Moscow with subsidiaries in Russia and Ukraine, business and logistics operations around the world. CDRI collaborates with pharmaceutical and biotech partners by enabling them to accelerate R&D programs to higher value inflection points. One of the industry's most established CRO, CDRI offers integrated Discovery outSource(TM) solutions that cover a complete range of disciplines needed to bring a new project in CNS, oncology, inflammation, metabolic, infectious and other diseases from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept, including Phases I-III and to market registration.

Filing Data

Not available.

Contract

Not available.